Omarigliptin · Marizev
Small molecule
Also known as MK-3102
Evidence outlook
Approved: Type 2 diabetes in adults, once-weekly 25 mg and 12.5 mg tablets (Marizev); Japan was the... (JP)
This approval is outside the US-scoped market view; US development of the covered program was discontinued (see the status note below). Regulatory approval supersedes design-level evidence grading for the approved use.
Also approved (1)
- Type 2 diabetes in adults, once-weekly 25 mg and 12.5 mg tablets (Marizev); Japan was the first country to approve it
Development in Type 2 Diabetes stopped (2016-04) as a strategic decision by the sponsor. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
No investor-visible indication is recorded for this drug.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other DPP-4 drugs
Alogliptin, Linagliptin, Saxagliptin, Sitagliptin, Anagliptin and 11 more. Compare all 17 DPP-4 drugs
This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Omarigliptin (Marizev): this drug | Phase 3 | Small molecule | DPP-4 | not yet graded | NCT01755156: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A) (Baseline and Week 24): Omarigliptin (Phase A) -0.54 Percent (95% CI -0.69 to -0.4) vs Placebo to Omarigliptin (Phase A) 0 Percent (95% CI -0.14 to 0.15) NCT01698775: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Baseline and Week 24): Omarigliptin (Phase A) -0.77 Percent (95% CI -1 to -0.54) vs Placebo to Omarigliptin (Phase A) -0.44 Percent (95% CI -0.67 to -0.21) | |
| Alogliptin (Nesina) | Approved(overall) | Small molecule | DPP-4 | Partial signal | NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8% | |
| Linagliptin (Tradjenta) | Approved(overall) | Small molecule | DPP-4 | Reliable signal | NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed | |
| Saxagliptin (Onglyza) | ApprovedUS marketing discontinued (overall) | Small molecule | DPP-4 | Reliable signal | NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1) | |
| Sitagliptin (Januvia) | Approved(overall) | Small molecule | DPP-4 | Partial signal | NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3) | |
| Anagliptin (Suiny) | Phase 3(overall) | Small molecule | DPP-4 | Reliable signal | NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established. | |
| Cofrogliptin | Phase 3(overall) | Small molecule | DPP-4 | Reliable signal | NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001 | |
| Evogliptin (Suganon) | Phase 3(overall) | Small molecule | DPP-4 | Reliable signal | NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001) NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority. | |
| Gemigliptin (Zemiglo) | Phase 3(overall) | Small molecule | DPP-4 | Reliable signal | NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%. NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001 | |
| Gosogliptin | Phase 3(overall) | Small molecule | DPP-4 | Partial signal | NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53). | |
| Prusogliptin (Shanzeping) | Phase 3(overall) | Small molecule | DPP-4 | Reliable signal | NCT04161430: HbA1c change from baseline at week 24: -0.63% (DBPR108) vs -0.02% (placebo); treatment difference -0.61 percentage points (95% CI -0.77% to -0.44%). DBPR108 was superior to placebo. NCT04218734: Change in HbA1c at week 24: −0.70% (DBPR108 + metformin) vs −0.07% (placebo + metformin); upper limit of the 95% CI for the between-group difference was −0.39, below the 0% superiority margin (P < .001). | |
| Retagliptin | Phase 3(overall) | Small molecule | DPP-4 | Partial signal | No reviewed efficacy summary | |
| Teneligliptin (Tenelia) | Phase 3(overall) | Small molecule | DPP-4 | Reliable signal | NCT01805830: Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL). NCT01798238: Change in HbA1c at week 24, teneligliptin 20mg vs placebo: difference -0.94% (LS mean 95% CI -1.22, -0.65), p<0.001; fasting plasma glucose difference -1.21 mmol/L (95% CI -1.72, -0.70), p<0.001. | |
| Trelagliptin (Zafatek) | Phase 3(overall) | Small molecule | DPP-4 | Partial signal | NCT02512068: Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089) NCT02324569: Change in HbA1c From Baseline at the End of Treatment Period I (End of Treatment Period I - End of the Screening Period) (End of the screening period (Week 0) and End of Treatment Period I (Up to Week 12)): Treatment Group I -0.56% ± 0.070 vs Treatment Group II 0.07% ± 0.067; p=<0.0001 (Treatment Group I vs Treatment Group II) | |
| Vildagliptin (Galvus) | Phase 3(overall) | Small molecule | DPP-4 | Partial signal | NCT00099866: At the study end, significant HbA(1c) reductions from baseline were seen with both vildagliptin (-1.0 +/- 0.1%, P < 0.001) and metformin (-1.4 +/- 0.1%, P < 0.001) missed | |
| Yogliptin | Phase 3(overall) | Small molecule | DPP-4 | Partial signal | No reviewed efficacy summary | |
| Retagliptin / Metformin (Ruilintang) | Phase 1(overall) | Small molecule | DPP-4, AMPK | Partial signal | No reviewed efficacy summary |
Upcoming events
No upcoming readouts on record for this asset.